

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **May 13, 2022**

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35023

(Commission File Number)

26-2797813

(IRS Employer Identification No.)

**8800 HSC Parkway
Bryan, Texas 77807**

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant's telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	IBIO	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 is furnished with this Current Report on Form 8-K.

<u>Exhibit Number</u>	<u>Exhibit Description</u>
99.1	Corporate Presentation of iBio, Inc. dated May 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 13, 2022

IBIO, INC.

By: /s/ Thomas F. Isett

Name: Thomas F. Isett

Title: Chief Executive Officer



Growing Tomorrow's Biologics

CORPORATE PRESENTATION
May 2022

Tom Isett, Chairman & CEO



© 2022 iBio, Inc. All Rights Reserved.

Forward-Looking Statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines and IBIO-101, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company's most recent Annual Report on Form 10-K and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.



Unique Solution for Some of the Industry's Biggest Problems

Biopharmaceutical Development Challenges



Time / Cost

>1 year & ~\$3-7M for scalable bioprocess & Ph1 material¹



Program Failures

Only ~5 in 5,000 drug concepts reach the clinic



Biomanufacturing


Drug industry is 55% more emissions intensive than the auto industry²

Our Solutions

iBio
SOLUTIONS




 **FastPharming**[®]

 **Glycaneering**SM


Dev/Mfg Services


Green Protein Expression System

FastPharming®
130,000 sf Facility




The Speed & Scalability of *FastPharming* Potentially Enables a Faster, More Efficient Path to the Clinic



 **FastPharming**® brings the capability to avoid the significant cost and time associated with selecting, developing & banking mammalian cell lines

iBio Platform Potentially Enables More Promising Candidates to Reach the Clinic, Faster

Current Drug Development Challenge



Industry Benchmarks to Reach IND¹


- 

Success Rate
<5 in 5,000
- 

Time
>4 Years
- 


Cost
>\$20M

FastPharming® + Glycanengineering Technology



Increased Potency with Glycanengineering


Reducing Single-Use Plastic Disposables in Upstream Processing



VS



Pipeline Advancing Vertically – and Horizontally





Therapeutics

Oncology & Fibrosis

Deploying AI-based Target ID & Glycanering in Immuno-Oncology to Create More, Higher-Quality, Shots-on-Goal


1 More shots-on-goal, sooner

2 Identifying failures earlier, saving costs

3 Accelerating development timelines



As programs advance through preclinical testing, iBio has additional opportunities to partner molecules and supply with **FastPharming** Services




THERAPEUTICS



IBIO-101 Stimulates Anti-tumor Immunity via anti-CD25 T_{reg} Depletion

IBIO-101/RTX-003



2nd gen IL-2 sparing anti-CD25 antibody selectively targets T_{regs} without blocking IL-2 signaling to T_{effs}

Positive IBIO-101/RTX-003 preclinical data are consistent with results from one other non-IL2 blocking anti-CD25 antibody that is now in a Phase I clinical trial¹

THERAPEUTICS


ibio

¹Data on file
 T_{reg} = Regulatory T Cells; T_{eff} = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity

IBIO-101/RTX-003 Inhibits Tumor Growth, Alone and in Combination


Greater potency was achieved with afucosylated version of the molecule produced with **FastPharming**

Monotherapy reduced tumor growth
in a dose-dependent manner



Lymphoma Xenograft Model¹

RTX-003 + anti-PD-1 antibody reduced
tumor growth and caused regression



Adenocarcinoma Model²

THERAPEUTICS

iBio

¹In vivo xenograft mouse model of lymphoma; Administration: 3x / week, i.p.; n=5 per group
²In vivo transgenic hCD25 mouse model; Admin: i.p. 3X / week at a single dose (1.5 mg/Kg) in combination with 2.5 mg/Kg of anti-mouse PD-1 antibody; n=5/group


IBIO-101 Has Showed Equivalent Efficacy and Potency with RTX-003

Potent ADCC with afucosylated plant-made molecule




IBIO-101 binding kinetic profiles are similar in CHO and plant-based expression system


Enabled engineering of more potent version without incremental IP access costs



Afucosylated IBIO-101 Enhanced ADCC Activity



Afucosylated IBIO-101 Elicited Potent Cancer Cells Killing via Human PBMC



Antibody	k_{on} (M ⁻¹ s ⁻¹)	k_{off} (s ⁻¹)	K_D (nM)	K_D SD (nM)
IBIO-101 CHO WT	4.71×10^5	1.92E-03	4.10	0.37
IBIO-101 CHO afuc	4.99×10^5	1.91E-03	3.9	1.00
IBIO-101 Plant WT	4.35×10^5	1.90E-03	4.20	0.89
IBIO-101 Plant afuc	4.92×10^5	2.07E-03	4.27	1.27
Dadizumab	4.15×10^5	7.60E-03	0.13	0.07

THERAPEUTICS



Phan, et al. Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer

Endostatin Derived Drugs for Fibrotic Disorders and Fibrotic Tumors


IBIO-100

Reduces fibrosis by impacting extracellular matrices¹

Pre-clinical data shows reduced fibrosis in scleroderma/IPF models & human lung explants¹

Orphan Drug Designation for systemic scleroderma received

Bleomycin Pre-Clinical Model²



Fibrotic Tissue

100µg IBIO-100 3x/week

Endostatin E4 for Fibrotic Tumors

Cancer-associated fibroblasts [CAFs] are one of the most abundant and critical components of tumor tissue:

- Can promote or retard tumorigenesis in a context-dependent manner
- Recent studies have revealed their roles in immune evasion and poor responses to cancer immunotherapy²
- Response to chemotherapy is highly variable³

UTSouthwestern
Medical Center

THERAPEUTICS



¹Data on file ²Liu T, Han C, Wang S et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. *J Hematol Oncol* 12, 86 (2019). <https://doi.org/10.1186/s13045-019-0770-1>
³Sonnenberg, M, van der Kuip, H, Haubel, S et al. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast *BMC Cancer* 8, 364 (2008). <https://doi.org/10.1186/1471-2407-8-364>



Vaccines

Human Health: COVID-19
Animal Health: CSFV

Experts Calling for Approaches Like iBio's "DAVI" Vaccine Design

We need to work towards a 'last dose', not a 'next dose'




"Vaccination strategies based on repeated booster doses of the original vaccine composition are unlikely to be appropriate or sustainable."



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Boosters are *"not something that should be repeated constantly"...* it could lead to *"problems with immune response."*

Antigen-adjuvant combos that may deliver long-lasting immunity



Lower cost vaccines & alternative routes of administration

Less mutable antigens to protect against emerging variants

VACCINES



¹ Boria, Bright, and Emanuel, *A National Strategy for COVID-19 Medical Countermeasures*. JAMA. 2022;327(3):215-216

IBIO-202 Nucleocapsid [N]-based Subunit Vaccine May Complement Current and Future Spike [S]-based Vaccines



N protein function is critical to viral genome packaging and is more highly conserved than the S protein. Thus, new viral variants may be less likely to escape N-based vaccines¹




N-antigen more effective than S in stimulating Natural Killer cell activation²



Prospectively suitable for delivery via routes other than intramuscular injection



Antigen produced in our rapidly scalable **FastPharming** System




VACCINES

iBio


¹ Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. *Nature Reviews Immunology* 21, 73–82 (2021);
² Fielding CA, et al. ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies. *bioRxiv*, (April 2021)

IBIO-202 Preclinical Data Shows Potential for Protective Humoral & Cell-mediated Immune Responses

Antibody Response




IBIO-202 desired Th1 skew indicative of a protective, not inflammatory, immune response




T-cell Response

High number of N-specific IFN γ secreting T cells indicates immune activation



Low number of IL-5 & IL-13 secreting cells indicates T-cell priming



VACCINES



iBio data on file


Emerging Studies Reinforce Value of IBIO-202's Design

Potential for a pan-betacoronavirus vaccine strengthening

Our antigen has an epitope predicted to provide cross-protection to other betacoronaviruses

Nucleocapsid-based induction of mature T cells adds benefit to more rapid containment of infection as variants overtake the prevailing strains²


VACCINES




"N-, not S-, reactive T cells play a protective role"¹

254 COVID-19+ patients
760 sampling visits

SARS-CoV-2 Specificities




IgG Antibodies to Other Human Coronaviruses



¹Kundu, R., Narean, J.S., Wang, L. et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun* 13, 80 (2022)
²Cohen, et al. *Cell Reports Medicine*. July 2021.

IBIO-202 Appears Differentiated in a Crowded Field



- N-directed vaccines may provide protection from COVID's neurological effects that S vaccines may not¹
- Simpler N-only design could improve access with lower COGS
- Potential pan-betacoronavirus effects could obviate the need for spike antigen vaccination

VACCINES

■ Spike Only ■ Nucleocapsid

Source: GlobalData database of drugs in development by targeted antigen

■ N only (US & global companies)
 ■ N only (academic, government, ex-US)
 ■ SHNM) or other combination
 ■ SHN



¹Dangi, Tanushree et al. "Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2." Cell reports vol. 36,10 (2021)



Classical Swine Fever



Classical Swine Fever [CSF] is a Significant World-Wide Economic Burden and Puts Major Export Markets at Risk

Vaccination control programs are essential to manage outbreaks and regain trade status

- CSF is a priority agricultural **biothreat**
- CSF poses a risk to **\$7.0B** US swine exports
- Only **38** countries are currently CSF-free
- **No vaccines** are approved in the US (only a few for emergency use)
- Current emergency use CSF vaccines have **drawbacks**
 - Modified live vaccines do not facilitate international trade
 - Recombinant vaccines can be expensive






VACCINES


iBio

<https://www.oie.int/en/disease/classical-swine-fever/#ui-id-2>


IBIO-400 Offers Potential Benefits Over Current Alternatives

-  Provides single-dose protection against CSF¹
-  Supports important trade requirements, unlike live virus vaccines
-  Potential to be the first CSF vaccine fully licensed by USDA

VACCINES



A single dose of IBIO-400 provides protection for pigs



iBio

¹ In studies

In Summary



Our Leadership Team Brings Drug Development & Bioprocessing Experience



Tom Iseff
CEO & Chairman



Martin Brenner, DVM, Ph.D.
CSO



Robert Lutz, MBA
CFBO



Marc Banjak
GC



Lisa Middlebrook
CHRO



Strong and Growing IP Estate Provides Exclusivity for iBio's Pipeline

104

Issued Patents
(30 U.S.)

29

Active Applications
(10 U.S.)



**More
Applications**

progressing to filing

Patent Protection Includes:

- IP for iBio's pipeline products and vaccines
- IP related to the **FastPharming** Protein Expression System
- Elements of **Glycaneering** Service for advanced glycosylation controls in plants, including afucosylation for Antibody-Dependent Cellular Cytotoxicity [ADCC]

Continuing to Aggressively Defend our Intellectual Property

- Settled *iBio v. Fraunhofer USA* for \$28M in May 2021



Financial Overview

- Publicly traded (NYSEA: IBIO) since Jan 2008
- Approximately \$48.6M in cash and cash equivalents plus investments in debt securities, excluding \$5.9M of restricted cash (31 Mar 2022)
- Approximately 218.2M common shares & 17.1M options, restricted stock units and warrants outstanding (31 Mar 2022)
- Texas Manufacturing Facility
 - Purchased in Nov 2021 with approximately \$22.4M debt (secured by the facility), \$6M in cash, and 1.3M warrants
 - Evaluating sale-leaseback to extinguish debt and recover cash
- Current cash provides runway through Sept 30, 2023



iBio: Leveraging Capabilities to Create Shareholder Value

